Large-scale ex vivo expansion and characterization of natural killer cells for clinical applications

Cytotherapy

Volumn 14, Issue 9, 2012, Pages 1131-1143

  Lapteva, Natalia ^a   Durett, April G ^a   Sun, Jiali ^a   Rollins, Lisa A ^a   Huye, Leslie L ^a   Fang, Jian ^a   Dandekar, Varada ^a   Mei, Zhuyong ^a   Jackson, Kimberley ^a   Vera, Juan ^a   Ando, Jun ^a   Ngo, Minhtran C ^b   Coustan Smith, Elaine ^c   Campana, Dario ^c   Szmania, Susann ^d   Garg, Tarun ^d   Moreno Bost, Amberly ^d   Vanrhee, Frits ^d   Gee, Adrian P ^a,b   Rooney, Cliona M ^a,b  

^a TEXAS CHILDREN S HOSPITAL   (United States)

^b BAYLOR COLLEGE OF MEDICINE   (United States)

^c NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^d UNIVERSITY OF ARKANSAS MEDICAL CENTER   (United States)

Author keywords

Cell based; Ex vivo expansion; Gas permeable static cell culture flasks (G Rex); Immunotherapy; Natural killer cells; Therapy

Indexed keywords

CD137 LIGAND; CD3 ANTIGEN; CD56 ANTIGEN; HLA ANTIGEN CLASS 1; INTERLEUKIN 15;

ANTIGEN EXPRESSION; APHERESIS; ARTICLE; CD3+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL COUNT; CELL CULTURE; CELL EXPANSION; CELL FUNCTION; CELL GROWTH; CELL LINE; CELL STIMULATION; CONTROLLED STUDY; CRYOPRESERVATION; CYTOTOXICITY; EX VIVO STUDY; FEEDING; GAS PERMEABILITY; HUMAN; HUMAN CELL; NATURAL KILLER CELL; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; RECEPTOR UPREGULATION; SUPERNATANT;

EID: 84866501841     PISSN: 14653249     EISSN: 14772566     Source Type: Journal    
DOI: 10.3109/14653249.2012.700767     Document Type: Article

References (38)

1. Imai K, Matsuyama. S, M iyake S, S uga K, N akachi K. Natural cytotoxic activity of peripheral-blood lymphocytes and cancer incidence: An 11-year follow-up study of a general population. Lancet. 2000; 356 : 1795 - 9.
2. Piroozmand A., Hassan ZM. E valuation of natural killer cell activity in pre and post treated breast cancer patients. J Cancer Res Ther. 2010; 6 : 478 - 81.
3. Dewan MZ, T akada M, T erunuma H, D eng X, A hmed S, Yamamoto N, et al. Natural killer activity of peripheral-blood mononuclear cells in breast cancer patients. Biomed Pharmacother. 2009; 63 : 703 - 6.
4. Kondo E, K oda K, T akiguchi N, O da K, S eike K, I shizuka M, et al. Preoperative natural killer cell activity as a prognostic factor for distant metastasis following surgery for colon cancer. Dig Surg. 2003; 20 : 445 - 51.
5. Ishigami S, N atsugoe S, T okuda K, N akajo A, X iangming C, Iwashige H, et al. Clinical impact of intratumoral natural killer cell and dendritic cell infi ltration in gastric cancer. Cancer Lett. 2000; 159 : 103 - 8.
6. Sconocchia G, Z lobec I, L ugli A, C alabrese D, I ezzi G, Karamitopoulou E, et al. Tumor infi ltration by FcgammaRIII (CD16) - myeloid cells is associated with improved survival in patients with colorectal carcinoma. Int J Cancer. 2011; 128 : 2663 - 72.
7. Al-Shibli K, A l-Saad S, D onnem T, P ersson M, B remnes RM, Busund LT. The prognostic value of intraepithelial and stromal innate immune system cells in non-small cell lung carcinoma. Histopathology. 2009; 55 : 301 - 12.
8. Villegas FR, C oca S, V illarrubia VG, J imenez R, C hillon MJ, Jareno J, et al. Prognostic signifi cance of tumor infi ltrating natural killer cells subset CD57 in patients with squamous cell lung cancer. Lung Cancer. 2002; 35 : 23 - 8.
9. Terme M, U llrich E, D elahaye NF, C haput N, Z itvogel L. Natural killer cell-directed therapies: Moving from unexpected results to successful strategies. Nat Immunol. 2008; 9 : 486 - 94.
10. Miller JS, S oignier Y, P anoskaltsis-Mortari A, M cNearney SA, Yun GH, Fautsch SK, et al. Successful adoptive transfer and in vivo expansion of human haploidentical NK cells in patients with cancer. Blood. 2005; 105 : 3051 - 7.
11. Arai S, M eagher R, S wearingen M, M yint H, R ich E, Martinson J, et al. Infusion of the allogeneic cell line NK-92 in patients with advanced renal cell cancer or melanoma: A phase I trial. Cytotherapy. 2008; 10 : 625 - 32.
12. Naume B, Gately M, E spevik T. A comparative study of IL-12 (cytotoxic lymphocyte maturation factor)-, IL-2-, and IL-7-induced effects on immunomagnetically purifi ed CD56 - NK cells. J Immunol. 1992; 148 : 2429 - 36.
13. Carson WE, F ehniger T A, H aldar S, E ckhert K, L indemann MJ, Lai C.F, et al. Apotential role for interleukin-15 in the regulation of human natural killer cell survival. J Clin Invest. 1997; 99 : 937 - 43.
14. Robertson M J, C ameron C, L azo S, C ochran K J, V oss S D, Ritz J. Costimulation of human natural killer cell proliferation: Role of accessory cytokines and cell contact-dependent signals. Nat Immun. 1996; 15 : 213 - 26.
15. Perussia B, R amoni C, A negon I, C uturi MC, F aust J, Trinchieri G. Preferential proliferation of natural killer cells among peripheral blood mononuclear cells cocultured with B lymphoblastoid cell lines. Nat Immun Cell Growth Regul. 1987; 6 : 171 - 88.
16. Miller JS, O elkers S, V erfaillie C, M cGlave P. R ole of monocytes in the expansion of human activated natural killer cells. Blood. 1992; 80 : 2221 - 9.
17. Imai C, Iwamoto S, Campana D. G enetic modifi cation of primary natural killer cells overcomes inhibitory signals and induces specifi c killing of leukemic cells. Blood. 2005; 106 : 376 - 83.
18. Fujisaki H, Kakuda H, Shimasaki N, Imai C, Ma J, Lockey T. et al. Expansion of highly cytotoxic human natural killer cells for cancer cell therapy. Cancer Res. 2009; 69 : 4010 - 7.
19. Vera JF, B renner LJ, G erdemann U, N go MC, S ili U, L iu H, et al. Accelerated production of antigen-specifi c T cells for preclinical and clinical applications using gas-permeable rapid expansion cultureware (G-Rex). J Immunother. 2010; 33 : 305 - 15.
20. Lapteva N., Vera JF. O ptimization manufacture of virus- and tumor-specifi c T cells. Stem Cells Int; 2011 : 434392.
21. Garg T K., Szmania SM, K han JA, H oering A, M albrough PA, Moreno-Bost A, et al. Highly activated and expanded natural killer cells for multiple myeloma immunotherapy. Haematologica. 2012; in press.
22. Garson D, D okhelar M C, W akasugi H, M ishal Z, T ursz T. HLA class-I and class-II antigen expression by human leukemic K562 cells and by Burkitt-K562 hybrids: Modulation by differentiation inducers and interferon. Exp Hematol. 1985; 13 : 885 - 90.
23. Chen E, Karr RW, F rost JP, G onwa TA, G inder GD. G amma interferon and 5-azacytidine cause transcriptional elevation of class I major histocompatibility complex gene expression in K562 leukemia cells in the absence of differentiation. Mol Cell Biol. 1986; 6 : 1698 - 705.
24. Sutherland J, M annoni P, R osa F, H uyat D, T urner AR, Fellous M. Induction of the expression of HLA class I antigens on K562 by interferons and sodium butyrate. Hum Immunol. 1985; 12 : 65 - 73.
25. Takemura Y, K oide Y, K awabata M, K itajima S, O hba C, Suzuki H. et al. Synergistic enhancement of class I major histocompatibility complex antigen expression in K562 cells induced by recombinant human interferon-gamma and tumor necrosis factor in combination. Exp Hematol. 1989; 17 : 795 - 9.
26. Spanholtz J, Preijers F, Tordoir M, Trilsbeek C, Paardekooper J, de Witte, et al. Clinical-grade generation of active NK cells from cord blood hematopoietic progenitor cells for immunotherapy using a closed-system culture process. PLoS One. 2011; 6 : e20740.
27. Sutlu T, S tellan B, G illjam M, Q uezada HC, N ahi H, Gahrton G, et al. Clinical-grade, large-scale, feeder-free expansion of highly active human natural killer cells for adoptive immunotherapy using an automated bioreactor. Cytotherapy. 2010; 12 : 1044 - 55.
28. Shimasaki N, F ujisaki H, C ho D, M asselli M, L ockey T, Eldridge P, et al. Aclinically adaptable method to enhance the cytotoxicity of natural killer cells against B-cell malignancies. Cytotherapy. 2012; 14 : 830 - 40.
29. Klingemann HG, Martinson J. Ex vivo expansion of natural killer cells for clinical applications. Cytotherapy. 2004; 6 : 15 - 22.
30. Koehl U, E sser R, Z immermann S, T onn T, K otchetkov R, Bartling T, et al. Ex vivo expansion of highly purifi ed NK cells for immunotherapy after haploidentical stem cell transplantation in children. Klin Padiatr. 2005; 217 : 345 - 50.
31. Decot V, V oillard L, L atger-Cannard V, A issi-Rothe L, Perrier P, Stoltz J.F, et al. Natural-killer cell amplifi cation for adoptive leukemia relapse immunotherapy: Comparison of three cytokines, IL-2, IL-15, or IL-7 and impact on NKG2D, KIR2DL1, and KIR2DL2 expression. Exp Hematol. 2010; 38 : 351 - 62.
32. Siegler U, M eyer-Monard S, J orger S, S tern M, T ichelli A, Gratwohl A, et al. Good manufacturing practice-compliant cell sorting and large-scale expansion of single KIR-positive alloreactive human natural killer cells for multiple infusions to leukemia patients. Cytotherapy. 2010; 12 : 750 - 63.
33. McKenna D H Jr, Sumstad D., Bostrom N, K adidlo D M, Fautsch S, McNearney S, et al. Good manufacturing practice production of natural killer cells for immunotherapy: A six-year single-institution experience. Transfusion. 2007; 47 : 520 - 8.
34. Carlens S, G illjam M, C hambers B J, A schan J, G uven H, Ljunggren H.G, et al. Anew method for in vitro expansion of cytotoxic human CD3 - CD56 - natural killer cells. Hum Immunol. 2001; 62:1092 - 8.
35. Suck G., O ei VY, L inn YC, H o SH, C hu S, C hoong A., et al. Interleukin-15 supports generation of highly potent clinical-grade natural killer cells in long-term cultures for targeting hematological malignancies. Exp Hematol. 2011; 39 : 904 - 14.
36. Somanchi SS, S enyukov VV, D enman CJ, L ee DA. E xpansion, purifi cation, and functional assessment of human peripheral blood NK cells. J Vis Exp. 2011.
37. Alici E, S utlu T, B jorkstrand B, G illjam M, S tellan B, Nahi H, et al. Autologous antitumor activity by NK cells expanded from myeloma patients using GMP-compliant components. Blood. 2008; 111 : 3155 - 62.
38. Lee D A., Verneris M R, C ampana D. A cquisition, preparation, and functional assessment of human NK cells for adoptive immunotherapy. Methods Mol Biol. 2010; 651 : 61 - 77.